Novartis vows to challenge heart drug patent loss

11-07-2023

Muireann Bolger

Novartis vows to challenge heart drug patent loss

Taljat David / Shutterstock.com

Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.


Novartis, Orange Book, Entresto, patent, Mylan, generics

LSIPR